IP Verse

Neuefeind competitive analysis

Explore patent oppositions filed by Neuefeind against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 3, 2026

Patent Number	Title	Applicant	Opposition Date
EP3519049	Safe And Effective Method Of Treating Psoriasis With Anti-Il23 Specific Antibody	JANSSEN BIOTECH	Sep 3, 2026
EP4364724	High Concentration Vegf Receptor Fusion Protein Containing Formulations	REGENERON PHARMACEUTICALS	Aug 25, 2026
EP4374919	Methods For Treating Atopic Dermatitis By Administering An Il-4R Antagonist	REGENERON PHARMACEUTICALS	Jul 28, 2026
EP4185318	Extended, High Dose Vegf Antagonist Regimens For Treatment Of Angiogenic Eye Disorders	BAYER HEALTHCARE	Jun 2, 2026
EP3487881	Methods Of Treating New-Onset Plaque Type Psoriasis Using Il-17 Antagonists	NOVARTIS	May 20, 2025
EP3330279	Method For Purifying Composition Comprising Antibodies With Anionic Polymer	CHUGAI SEIYAKU KABUSHIKI KAISHA	Jan 5, 2023
EP3393234	Restorer Plants	KWS SAAT	Sep 15, 2022
EP3470432	Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist	REGENERON PHARMACEUTICALS	Jul 6, 2022
EP3107575	Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist	REGENERON PHARMACEUTICALS	Jun 1, 2022
EP2445924	Capture Purification Processes For Proteins Expressed In A Non-Mammalian System	AMGEN	Dec 3, 2021

Discover the latest PTAB cases involving Neuefeind, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Neuefeind with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 3, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
NEUEFEIND	34	-	-	-
CHUGAI SEIYAKU KABUSHIKI KAISHA	3	114	-	1
F HOFFMANN LA ROCHE	34	231	-	-
REGENERON PHARMACEUTICALS	55	142	9	32